The impeachment pretrial of Philippine Vice President Sara Duterte is nearing completion after stretching into a fifth day, as her defense team and House prosecutors moved to finalize the painstaking marking of thousands of pages of documentary evidence. The pretrial conference, which began on June 18, has focused on organizing and pre-marking evidence, identifying witnesses, and stipulating uncontested facts ahead of the full impeachment trial.

Defense lawyer and spokesperson Michael Poa said on Thursday he was "very optimistic" the pretrial could be finished by the end of the day, citing faster progress in recent sessions. Poa told reporters that at his own marking station he expected to complete work by around 3 p.m. or 4 p.m., and that other members of the defense team handling separate batches of documents shared a similarly optimistic outlook. He added that if the process needed more time, an extension into Friday would likely be the latest.

The bulk of the work has centered on Article I of the impeachment complaint, which concerns Duterte's alleged misuse of confidential funds and alone involves about 8,000 documents to be marked, according to Senate clerk of court Renato Bantug. Four mixed teams composed of prosecution and defense members, along with staff from the Office of the Senate Secretary acting as the clerk of court, have been assigned to handle the Article I materials, while two additional teams are processing evidence for Article II, which deals with Duterte's supposed unexplained wealth.

Earlier in the pretrial, both sides completed pre-marking evidence for Articles III and IV. Those articles include allegations that Duterte bribed officials of the Department of Education and accusations connected to purported threats against President Ferdinand Marcos Jr., First Lady Liza Marcos, and former House Speaker Martin Romualdez, which are framed in the complaint as bribery, corruption, and culpable violation of the Constitution, high crimes, and betrayal of public trust. The conference had initially been expected to conclude on its second day, but the volume of documents forced an extension to the scheduled fifth day, with additional teams deployed and working hours stretched in recent sessions to hasten the process.

Indonesia menambah amunisi dalam menangani beban penyakit metabolik yang kian berat dengan kehadiran tirzepatide, terapi inovatif untuk diabetes melitus tipe 2 dan obesitas. PT Anugerah Pharmindo Lestari (APL), bagian dari Zuellig Pharma, resmi menghadirkan obat agonis reseptor ganda glucose-dependent insulinotropic polypeptide (GIP) dan glucagon-like peptide-1 (GLP-1) pertama di pasar domestik setelah memperoleh persetujuan dari Badan Pengawas Obat dan Makanan (BPOM). Langkah ini dinilai strategis di tengah meningkatnya prevalensi diabetes dan obesitas di Indonesia.

Data International Diabetes Federation (IDF) Diabetes Atlas 2025 menunjukkan sekitar 20,4 juta penduduk Indonesia berusia 20–79 tahun hidup dengan diabetes, dan angka ini diproyeksikan naik menjadi 28,6 juta pada 2050 jika tidak ada pengendalian efektif. Survei Kesehatan Indonesia (SKI) 2023 mencatat prevalensi obesitas dewasa sudah mencapai 23,4 persen, lebih tinggi dibandingkan satu dekade lalu. Kombinasi dua kondisi tersebut meningkatkan risiko komplikasi serius seperti penyakit kardiovaskular dan gangguan ginjal kronis, sekaligus menekan kualitas hidup pasien.

APL menyebut peluncuran tirzepatide dimungkinkan berkat skema percepatan yang diterapkan BPOM. Obat ini mendapatkan izin edar dalam 98 hari kerja, sementara persetujuan indikasi untuk manajemen berat badan kronis diselesaikan hanya dalam 42 hari kerja melalui mekanisme reliance. Kebijakan percepatan yang mulai berlaku 1 Agustus 2025 memungkinkan obat inovatif yang telah disetujui di negara referensi dan memiliki dokumen lengkap diproses sekitar 90 hari kerja, tanpa menurunkan standar keamanan, khasiat, dan mutu. Kepala BPOM Taruna Ikrar menegaskan setiap produk tetap melalui evaluasi ilmiah menyeluruh meski memperoleh jalur cepat.

Taruna menyoroti bahwa sebelumnya banyak obat inovatif hanya tersedia di luar negeri sehingga pada praktiknya lebih mudah diakses kelompok berpendapatan tinggi yang mampu berobat ke negara tetangga seperti Singapura. Dengan persetujuan tirzepatide di dalam negeri, regulator berharap kesenjangan akses dapat diperkecil. Secara mekanisme, tirzepatide bekerja mengaktivasi dua reseptor hormon GIP dan GLP-1 yang meniru kerja hormon alami tubuh, membantu meningkatkan kerja insulin, mempercepat masuknya glukosa ke dalam sel, serta mencegah penumpukan gula di pembuluh darah yang dapat memicu aterosklerosis dan komplikasi lain. Di tengah kenaikan tajam kasus diabetes dan obesitas, kehadiran terapi ini diposisikan sebagai perluasan pilihan tatalaksana berbasis bukti ilmiah bagi pasien dan tenaga kesehatan di Indonesia.